We are live on ! Find out more
CAPR icon

Capricor Therapeutics
CAPR

18 hedge funds and large institutions have $677K invested in Capricor Therapeutics in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.76% less ownership

Funds ownership: 7.08% → 5.32% (-1.8%)

5% less funds holding

Funds holding: 19 → 18 (-1)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

93% less capital inflows, than outflows

Capital inflows: $31.2K | Capital outflows: $448K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$13.2K
2
UBS Group
UBS Group
Switzerland
+$10.5K
3
Virtu Financial
Virtu Financial
New York
+$7.25K
4
Northern Trust
Northern Trust
Illinois
+$238

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$381K
2
Brown Advisory
Brown Advisory
Maryland
-$56.5K
3
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
-$5.96K
4
Perceptive Advisors
Perceptive Advisors
New York
-$4K
5
Bank of America
Bank of America
North Carolina
-$659

CAPR Hedge Fund Activity: Q4 2018 in Review

18 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2018, worth a combined $677K — down 70% from $2.28M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CAPR and 0 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.

The largest buyer was Citadel Advisors, adding an estimated $13.2K. The largest seller was Vanguard Group, cutting an estimated $381K.

  • 18 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2018, down from 19 in Q3 2018.
  • Funds reported $677K of Capricor Therapeutics stock for Q4 2018, down 70% quarter-over-quarter.
  • 0 funds opened new Capricor Therapeutics positions in Q4 2018 and 1 closed out, a net change of -1 holder.
  • The largest Capricor Therapeutics buyer in Q4 2018 was Citadel Advisors, an estimated $13.2K added.
  • The largest Capricor Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $381K sold.

Based on aggregated 13F filings for Q4 2018.